Arlington Trust’s Sarepta Therapeutics SRPT Stock Holding History

Arlington Trust’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-38	Closed	-$4.75K	–	575
2024 Q3	$4.75K	Buy	+38	New	+$5.25K	﹤0.01%	499

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arlington Trust's SRPT Position: Q4 2024 in Review

Arlington Trust sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 38 shares — an estimated $4.75K sold.

Arlington Trust first reported a position in SRPT in Q3 2024 and held it in 1 quarter. The position peaked at $4.75K in Q3 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Arlington Trust reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Arlington Trust sold 38 Sarepta Therapeutics shares in Q4 2024, an estimated $4.75K.
Arlington Trust first reported a position in Sarepta Therapeutics in Q3 2024 and held it in 1 quarter.
Arlington Trust's Sarepta Therapeutics position peaked at $4.75K in Q3 2024.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Arlington Trust's 13F filing for Q4 2024, filed 29 Jan 2025.